Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Standard BioTools Inc LAB

Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.


NDAQ:LAB - Post by User

Post by Humaniston May 11, 2021 10:17am
214 Views
Post# 33172999

fldm is up on possible sale exploration of one of its bus

fldm is up on possible sale exploration of one of its bus

** Activist investor Caligan Partners built an 11% stake in Fluidigm Corp, which makes a COVID-19 test, and may urge the company to conduct a strategic review and explore a sale of one of its business units, two sources said on Monday. (Compiled by Niket Nishant in Bengaluru)


<< Previous
Bullboard Posts
Next >>